Your Best Stock

Bristol-Myers Squibb BMY

US equityMarket cap rank #122Drug Manufacturers - GeneralCancer Research
$60.72
−$0.44 (-0.71%)
Market open · Sep 24, 1:10 pm ET
After hours $61.34 +0.31%
Open$61.21
Prev close$61.15
Day range$60.60 – $61.57
Volume4.16M
Market cap$124.02B
P/E (TTM)13.4
Dividend yield4.13%

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$12.97B+5.7% YoY
Operating profit$4.03B+6.7% YoY
Net profit$3.32B+152.6% YoY
Diluted EPS$1.62+153.1% YoY
Free cash flow$3.09B-13.2% YoY
Operating cash flow$3.39B

Revenue, last 8 quarters

$11.9BSep '24$12.3BDec '24$11.2BMar '25$12.3BJun '25$12.2BSep '25$12.5BDec '25$11.5BMar '26$13.0BJun '26

Net profit, last 8 quarters

$1.2BSep '24$76.0MDec '24$2.5BMar '25$1.3BJun '25$2.2BSep '25$1.1BDec '25$2.7BMar '26$3.3BJun '26

Diluted EPS by quarter

0.60Sep '240.04Dec '241.20Mar '250.64Jun '251.08Sep '250.53Dec '251.31Mar '261.62Jun '26

Free cash flow by quarter

$5.3BSep '24$4.1BDec '24$1.7BMar '25$3.6BJun '25$6.0BSep '25$1.6BDec '25$757.0MMar '26$3.1BJun '26

Annual revenue

$42.5BFY20$46.4BFY21$46.2BFY22$45.0BFY23$48.3BFY24$48.2BFY25

Profitability & balance sheet

Gross margin70.2%
Operating margin28.1%
Net margin18.9%
Return on equity46.7%
Return on assets10.2%
Return on invested capital15.7%
Current ratio1.53
Liabilities / assets74.5%
Cash & investments$11.07B
Total debt$44.85B
Net cash (debt)-$33.78B
Free cash flow / sales23.3%

Where the revenue comes from

Quarter 2026/Q2

By business line

  • Eliquis$4.48B 34.5%
  • Opdivo$2.49B 19.2%
  • Other$1.49B 11.5%
  • Orencia$1.03B 8.0%
  • Yervoy$769.00M 5.9%
  • Reblozyl$735.00M 5.7%
  • Other Growth products$653.00M 5.0%
  • Breyanzi$484.00M 3.7%
  • Revlimid$425.00M 3.3%
  • Camzyos$416.00M 3.2%

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Revenue as Reported $12.97B $11.49B $48.19B $12.50B $12.22B
Total Operating Revenue $12.97B $11.49B $48.20B $12.50B $12.22B
Cost of Revenue $3.73B $3.42B $13.94B $4.10B $3.44B
Gross Profit $9.25B $8.07B $34.26B $8.41B $8.79B
Operating Expense $5.22B $4.70B $20.54B $5.59B $5.15B
Selling and Admin Expenses $1.83B $1.62B $7.27B $2.18B $1.79B
Research & Development $2.96B $2.65B $9.95B $2.59B $2.53B
Depreciation & Amortization & Depletion $437.00M $437.00M $3.32B $826.00M $831.00M
-Depreciation & Amortization $437.00M $437.00M $3.32B $826.00M $831.00M
Operating Profit $4.03B $3.37B $13.72B $2.81B $3.64B
Net Non-Operating Interest Income (Expense) -$407.00M -$411.00M -$1.89B -$432.00M -$480.00M
Non-Operating Interest Expense $407.00M $411.00M $1.89B $432.00M $480.00M
Other Income (Expense) $467.00M $284.00M -$2.50B -$909.00M -$44.00M
Gain on Sale of Security $215.00M $238.00M $510.00M -$18.00M $351.00M
Special Income (Charges) $60.00M -$122.00M -$5.23B -$1.59B -$909.00M
-Less:Restructuring and Mergern & Acquisition $73.00M $118.00M $4.79B $1.58B $744.00M
-Less:Other Special Charges $5.00M $4.00M $434.00M $10.00M $165.00M
-Gain on Sale Of Business $138.00M
Other Non-Operating Income (Expenses) $192.00M $168.00M $2.21B $699.00M $514.00M
Pretax Profit $4.09B $3.24B $9.33B $1.47B $3.11B
Tax $770.00M $561.00M $2.27B $384.00M $919.00M
Net Profit $3.32B $2.68B $7.06B $1.09B $2.20B
Profit from Continuing Operations $3.32B $2.68B $7.06B $1.09B $2.20B
Minority Interests -$1.00M $1.00M $2.00M -$1.00M -$6.00M
Net Income to Parent Company $3.32B $2.68B $7.05B $1.09B $2.20B
Net Income to Common Stockholders $3.32B $2.68B $7.05B $1.09B $2.20B
Basic EPS $1.62 $1.31 $3.47 $0.53 $1.08
Diluted EPS $1.62 $1.31 $3.46 $0.53 $1.08
Dividend Per Share $0.63 $0.63 $2.49 $0.63 $0.62
-Less:Impairment of Capital Assets $0.00

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $87.63B $86.48B $90.04B $90.04B $96.89B
Total Current Assets $28.58B $27.21B $29.39B $29.39B $35.63B
Cash and Cash Equivalents & Short-Term Investments $11.07B $10.49B $10.67B $10.67B $16.50B
-Cash and Cash Equivalents $8.72B $9.57B $10.21B $10.21B $15.73B
-Short Term Investments $2.35B $912.00M $464.00M $464.00M $776.00M
Receivables $13.00B $12.08B $14.53B $14.53B $14.62B
-Accounts Receivable $9.08B $7.95B $9.59B $9.59B $9.62B
-Taxes Receivable $2.34B $2.57B $2.92B $2.92B $2.97B
-Other Receivables $1.58B $1.57B $2.01B $2.01B $2.02B
Inventory $2.74B $2.76B $2.69B $2.69B $2.76B
Other Current Assets $1.78B $1.88B $1.50B $1.50B $1.75B
Total Non-Current Assets $59.06B $59.27B $60.65B $60.65B $61.26B
Net PPE $9.28B $9.19B $9.13B $9.13B $8.95B
-Gross PPE $14.83B $14.62B $14.42B $14.42B $14.15B
-Accumulated Depreciation -$5.55B -$5.43B -$5.29B -$5.29B -$5.20B
Investments and Advances $2.39B $2.24B $2.51B $2.51B $2.36B
-Available for Sale Securities $397.00M $366.00M $396.00M $396.00M
-Long Term Equity Investment $1.99B $1.88B $2.10B $2.10B $1.94B
Goodwill and Other Intangible Assets $39.37B $40.23B $41.11B $41.11B $42.47B
-Goodwill $21.74B $21.74B $21.75B $21.75B $21.75B
-Other Intangible Assets $17.63B $18.49B $19.35B $19.35B $20.73B
Defined Pension Benefit $332.00M $330.00M $330.00M $330.00M $281.00M
Non-Current Deferred Assets $5.36B $5.18B $5.38B $5.38B $4.96B
Other Non-Current Assets $2.33B $2.10B $2.20B $2.20B $2.24B
Total Liabilities $65.32B $66.37B $71.53B $71.53B $78.29B
Total Current Liabilities $18.66B $19.16B $23.42B $23.42B $28.14B
Payables $6.25B $6.43B $5.84B $5.84B $6.57B
-Accounts Payable $4.16B $4.23B $3.58B $3.58B $4.29B
-Total Tax Payable $806.00M $909.00M $979.00M $979.00M $1.02B
-Dividends Payable $1.29B $1.29B $1.28B $1.28B $1.26B
Current Accrued Expenses $587.00M $507.00M $484.00M $484.00M $512.00M
Short-Term Debt and Capital Lease Obligation $1.23B $2.51B $2.46B $2.46B $4.72B
-Current Debt $1.03B $2.31B $2.26B $2.26B $4.51B
-Current Capital Lease Obligation $207.00M $199.00M $202.00M $202.00M $214.00M
Other Current Liabilities $9.71B $9.22B $13.07B $13.07B $15.17B
Total Non-Current Liabilities $46.66B $47.22B $48.12B $48.12B $50.15B
Long Term Accounts Payable and Other Payables $830.00M $1.31B $1.41B $1.41B $1.74B
Long Term Debt and Capital Lease Obligation $43.82B $43.92B $44.68B $44.68B $46.32B
-Long Term Debt $42.09B $42.15B $42.85B $42.85B $44.47B
-Long Term Capital Lease Obligation $1.73B $1.77B $1.83B $1.83B $1.85B
Non-Current Deferred Liabilities $885.00M $842.00M $878.00M $878.00M $892.00M
Employee Benefits $307.00M $317.00M $330.00M $330.00M $393.00M
Other Non-Current Liabilities $815.00M $824.00M $824.00M $824.00M $811.00M
Total Equity $22.32B $20.10B $18.51B $18.51B $18.60B
Stockholders' Equity $22.32B $20.07B $18.47B $18.47B $18.55B
Capital Stock $292.00M $292.00M $292.00M $292.00M $292.00M
-Common Stock $292.00M $292.00M $292.00M $292.00M $292.00M
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $46.50B $46.37B $46.39B $46.39B $46.27B
Retained Earnings $20.32B $18.29B $16.90B $16.90B $17.09B
Less: Treasury Stock $43.50B $43.52B $43.58B $43.58B $43.59B
Gains/Losses Not Affecting Retained Earnings -$1.29B -$1.37B -$1.52B -$1.52B -$1.51B
Other Equity Interests $1.00M $1.00M
Minority Interests $0.00 $34.00M $33.00M $33.00M $48.00M
-Held to Maturity Securities $15.00M $15.00M $422.00M

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow $3.39B $1.10B $14.16B $1.97B $6.31B
Net cash flow from continuing operations $3.39B $1.10B $14.16B $1.97B $6.31B
Net Income from Continuing Operations $3.32B $2.68B $7.06B $1.09B $2.20B
Gain/Loss from Continuing Operations -$256.00M -$168.00M -$1.45B -$475.00M -$485.00M
Depreciation & Depletion & Amortization $594.00M $594.00M $4.01B $977.00M $1.01B
Deferred Tax -$195.00M $161.00M -$965.00M -$392.00M -$359.00M
Other Non-Cash Items $1.00M $115.00M $4.30B $1.72B $559.00M
Change in Working Capital -$624.00M -$2.83B -$455.00M -$1.65B $3.06B
-Change in Receivables -$1.18B $1.69B -$295.00M $19.00M $155.00M
-Change in Inventory -$36.00M $14.00M -$184.00M $71.00M -$90.00M
-Change in Payables and Accrued Expense -$551.00M $596.00M -$6.00M -$414.00M $1.05B
-Change In Other Working Capital $1.15B -$5.13B $30.00M -$1.33B $1.94B
Net cash flow from investing -$1.61B -$131.00M -$4.13B -$1.46B -$1.70B
Net Cash Flow from Continuing Investing Activities -$1.61B -$131.00M -$4.13B -$1.46B -$1.70B
Capital Expenditure -$305.00M -$347.00M -$1.31B -$370.00M -$320.00M
Net Business Purchase and Sale $118.00M $247.00M -$2.87B -$1.43B -$1.60B
Net Investment Purchase and Sale -$1.43B -$31.00M $52.00M $340.00M $213.00M
Financing Cash Flow -$2.63B -$1.56B -$10.35B -$6.03B -$1.49B
Net Cash Flow from Continuing Financing Activities -$2.63B -$1.56B -$10.35B -$6.03B -$1.49B
Net Issuance Payments Of Debt -$1.35B -$179.00M -$5.18B -$4.73B -$224.00M
Cash Dividends Paid -$1.29B -$1.28B -$5.05B -$1.26B -$1.26B
Proceeds from Stock Option Exercised $7.00M -$98.00M -$128.00M -$33.00M -$3.00M
Ending Cash Balance $8.72B $9.58B $10.22B $10.22B $15.73B
Net Change in Cash -$851.00M -$587.00M -$324.00M -$5.51B $3.12B
Beginning Cash Balance $9.58B $10.22B $10.35B $15.73B $12.61B
Effect of Exchange Rate Changes -$10.00M -$48.00M $195.00M $5.00M -$4.00M
Free Cash Flow $3.09B $757.00M $12.85B $1.60B $5.99B
Net Common Stock Issuance $0.00
Scroll to Top